Your new post is loading...
Neuraltus Pharmaceuticals Inc. will take its experimental Lou Gehrig’s disease drug into Phase III next year, representing a big move for the small Palo Alto company and a big victory for patients who fought to enroll an important mid-stage...
No comment yet.
Sign up to comment
